Paratek withdraws European marketing authorisation application for oral and intravenous Nuzyra in skin infections and pneumonia

Paratek Pharmaceuticals

17 October 2019 - Application approvable by EMA for skin infections based on two Phase 3 studies.

Paratek Pharmaceuticals announced today that the company has withdrawn its submission to the EMA of the marketing authorisation application for Nuzyra (omadacycline).

Based on the review of the data and the application, the EMA has recommended approval for Nuzyra for the treatment of acute bacterial skin and skin structure infections but not for community-acquired bacterial pneumonia. The EMA noted a second study is required for this indication; this position is consistent with EU guidance that typically requires two phase 3 studies per indication for approval.

Read Paratek Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe , Dossier